omeprazole has been researched along with caffeine in 109 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (12.84) | 18.2507 |
| 2000's | 25 (22.94) | 29.6817 |
| 2010's | 56 (51.38) | 24.3611 |
| 2020's | 14 (12.84) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Conradi, R; Lee, PH; Shanmugasundaram, V | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Brockmöller, J; Brösicke, H; Helge, H; Roots, I; Rost, KL; Scheffler, M | 1 |
| Golor, J; Helge, H; Krüger, N; Neubert, D | 1 |
| Hartmann, M; Huber, R; Radtke, HW; Steinijans, VW | 1 |
| Andersson, T; Bergstrand, R; Cederberg, C; Eriksson, S; Lagerström, PO; Skånberg, I | 1 |
| Andersson, T; Eriksson, S; Hässle, A; Walan, A | 1 |
| Avner, D; Greski-Rose, PA; Jennings, DE; Jhala, N; Robinson, M; Sahba, B | 1 |
| Brösicke, H; Heinemeyer, G; Roots, I; Rost, KL | 1 |
| Berthou, F; Carlhant, D; Gouerou, H; Nousbaum, JB; Riche, C; Robaszkiewicz, M | 1 |
| Roots, I; Rost, KL | 1 |
| Girre, C; Padoin, C; Palombo, S; Rizzo, N; Scherrmann, JM | 1 |
| Andersson, T; Holmberg, J; Röhss, K; Walan, A | 1 |
| Bertilsson, L; Böttiger, Y; Brynne, N; Hallén, B | 1 |
| Bliesath, H; Hartmann, M; Koch, H; Mascher, H; Steinijans, VW; Wurst, W; Zech, K | 1 |
| Bohnemeier, H; Brockmöller, J; Fuhr, U; Roots, I; Rost, KL; Thomsen, T; Zaigler, M | 1 |
| Bertino, JS; Bleakley, JF; Gaedigk, A; Gotschall, R; Kearns, GL; Kim, JS; Leeder, JS; Nafziger, AN; Streetman, DS | 1 |
| Andersson, K; Bertilsson, L; Carrillo, JA; Christensen, M; Dahl, ML; Mihara, K; Ramos, SI; Tybring, G; Yasui-Furokori, N | 1 |
| Chen, XP; Han, XM; Jiang, CH; Ouyang, DS; Shu, Y; Tan, ZR; Zhou, HH | 1 |
| Bernal, ML; Fanlo, A; Martínez-Ballarin, E; Mayayo, E; Sinués, B; Soriano, MA | 1 |
| Bertino, JS; Chainuvati, S; Gaedigk, A; Kashuba, AD; Kearns, GL; Leeder, JS; Nafziger, AN; Rowland, E; Sellers, E; Zhang, Y | 1 |
| Bernal, ML; Fanlo, A; Mayayo, E; Sinués, B; Val, M | 1 |
| Cherkaoui, S; Daali, Y; Dayer, P; Jerdi, MC; Oestreicher, MK | 1 |
| Fuhr, U; Kober, S; Mutschler, E; Spahn-Langguth, H; Zaigler, M | 1 |
| Booker, BM; Brazeau, D; Cloen, D; Frerichs, V; Frye, RF; Haas, CE; Kufel, T; Zaranek, C | 1 |
| Bertino, JS; Gaedigk, A; Kashuba, AD; Kearns, G; Leeder, JS; Nafziger, AN; Rowland, E; Sellers, E; Shelepova, T; Victory, J; Zhang, Y | 1 |
| Adkison, KK; Berrey, MM; Bertino, JS; Borland, J; Fang, L; Johnson, BM; Lou, Y; Nafziger, AN; Piscitelli, SC; Song, IH | 1 |
| Baxter-Meheux, F; Blake, MJ; Eron, JJ; Gaver, VE; Kashuba, AD; Klein, CE; Patterson, KB; Rezk, NL; Rublein, JC; Yeh, RF | 1 |
| Cha, IJ; Liu, KH; Ryu, JY; Shin, JG; Shon, JH; Song, IS; Sunwoo, YE | 1 |
| Andersson, TB; Bäckström, T; Bertilsson, L; Böttiger, Y; Bredberg, E; Diczfalusy, U; Kanebratt, KP; Sparve, E | 1 |
| Chem, MC; Chetty, M; Ghassabian, S; Glen, J; McLachlan, AJ; Murray, M; Rahme, J; Ramzan, I; Stankovic, Z; Tattam, BN | 1 |
| Cho, JY; Hong, JH; Jang, IJ; Kim, BH; Kim, J; Kim, KP; Lim, KS; Shin, SG; Yi, S; Yu, KS | 1 |
| Collins, DA; Deng, Y; Jenkins, J; Kitchen, VS; Williams, D | 1 |
| Boulenc, X; Brian, W; Donazzolo, Y; Poitiers, F; Santoni, A; Turpault, S; Van Horn, R | 1 |
| Chen, Y; Guo, Y; Klaassen, CD; Tan, ZR; Zhou, HH | 1 |
| Auwärter, V; Dresen, S; Lutz-Bonengel, S; Naue, J; Wohlfarth, A | 1 |
| Kim, DH; Oh, KS; Park, SJ; Shin, JG; Shinde, DD | 1 |
| Takayanagi, R; Teramoto, S; Uotsu, N; Yamada, M; Yamada, Y; Yamasaki, I | 1 |
| Iwasaki, K; Izumi, H; Kusumoto, S; Mogi, M; Murayama, N; Shimizu, M; Takehara, H; Toda, A; Utoh, M; Yamazaki, H | 1 |
| Chalasani, N; Hall, SD; Jones, DR; Mattar, S; Tandra, S; Vuppalanchi, R | 1 |
| Cui, J; Li, J; Li, R; Lin, W; Ling, X; Yang, H; Yu, N; Zhang, J | 1 |
| Brosen, K; Christensen, MM; Damkier, P; Pedersen, RS | 1 |
| Akamatsu, T; Chida, K; Inui, N; Karayama, M; Namiki, N; Tanaka, S; Uchida, S; Watanabe, H | 1 |
| Aharchi, F; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Leopold, L; Onkelinx, J; Peeters, M; Stevens, T; Van Solingen-Ristea, RM | 1 |
| Namiki, N; Tanaka, S; Uchida, S | 1 |
| Bosilkovska, M; Daali, Y; Déglon, J; Desmeules, J; Samer, C; Staub, C; Walder, B | 1 |
| de Andrés, F; Llerena, A; Sosa-Macías, M | 1 |
| Bosilkovska, M; Daali, Y; Dayer, P; Déglon, J; Desmeules, JA; Rebsamen, M; Samer, CF; Staub, C; Walder, B | 1 |
| Doogue, MP; Miners, JO; Polasek, TM; Rowland, A; Snyder, BD | 1 |
| Ikeda, K; Kim, S; Koyanagi, T; Murayama, N; Nakanishi, Y; Uehara, S; Uno, Y; Utoh, M; Yamaura, Y; Yamazaki, H; Yano, K | 1 |
| Cao, X; Huang, Y; Lan, YY; Li, YJ; Liao, SG; Liu, Y; Lu, Y; Tang, L; Wang, AM; Wang, YL; Zheng, L | 1 |
| Achterbergh, R; Boelen, A; de Vries, EM; Klümpen, HJ; Lammers, LA; Mathôt, RA; Romijn, JA; Soeters, MR; van Nierop, FS | 1 |
| Harris, G; Landesmann, B; Mennecozzi, M; Palosaari, T; Whelan, M | 1 |
| Corcoran, M; Ermer, J; Martin, P | 1 |
| Chen, D; Davis, HM; de Vries, DE; Leon, F; Marciniak, SJ; Xu, Z; Zhou, H; Zhuang, Y | 1 |
| Murayama, N; Shida, S; Shimizu, M; Uno, Y; Utoh, M; Yamazaki, H | 1 |
| Inoue, T; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H | 1 |
| Berger, B; Derungs, A; Donzelli, M; Haschke, M; Krähenbühl, S; Noppen, C | 1 |
| Bénech, H; Lenuzza, N; Nguyen, TT; Pruvost, A | 1 |
| Bovera, M; de Andrés, F; Fariñas, H; LLerena, A; Terán, E; Terán, S | 1 |
| Hellum, B; Nilsen, OG; Spigset, O; Thu, OK | 1 |
| Kawano, M; Mitsui, M; Sasaki, E; Shimizu, M; Suemizu, H; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H | 1 |
| Bosilkovska, M; Daali, Y; Déglon, J; Desmeules, J; Samer, C; Thomas, A; Walder, B | 1 |
| Achterbergh, R; Boelen, A; de Vries, EM; Klümpen, HJ; Lammers, LA; Mathot, RA; Romijn, JA | 1 |
| Jeon, JY; Kim, DS; Kim, MG; Kim, Y | 1 |
| Armani, S; Chun, DY; Darstein, C; Einolf, HJ; Gu, H; Kulkarni, S; Sauter, N; Ting, L; Tripathi, AP; Wang, L; Zhu, B | 1 |
| Achterbergh, R; Lammers, LA; Mathôt, RAA; Romijn, JA; van Schaik, RHN | 1 |
| Inoue, T; Kusama, T; Mogi, M; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H | 1 |
| Edwards, JE; Eliot, L; Karan, S; MacConell, L; Parkinson, A | 1 |
| Gajee, R; Papadopoulos, KP; Puzanov, I; Strickler, JH; Tachibana, M; Wang, Y; Zahir, H | 1 |
| Achterbergh, R; Lammers, LA; Mathôt, RAA; Romijn, JA | 1 |
| Gong, Z; Huang, J; Li, Y; Liu, C; Liu, T; Lu, Y; Pan, J; Sun, J; Wang, Y; Zheng, J; Zheng, L | 1 |
| Mangoni, AA; Rowland, A; Sorich, MJ; van Dyk, M; Warncken, D | 1 |
| Bailey-Smith, C; Bodrug, I; Cheng, A; Glasgow, XS; Hussain, A; Iwamoto, M; Khalilieh, S; Levine, V; Martinho, M; Mekokishvili, L; Montgomery, D; Shaw, PM | 1 |
| Choi, MK; Choi, WG; Han, YH; Heo, JK; Jo, J; Kang, WY; Lee, HS; Lee, HW; Lee, S; Liu, KH; Ohk, B; Seong, SJ; Song, IS; Yoon, YR | 1 |
| Cintra, MACT; Coelho, EB; Cusinato, DAC; Filgueira, GCO; Lanchote, VL; Rocha, A | 1 |
| Camez, A; Cheng, L; Ignatenko, S; Khatri, A; Othman, AA; Pang, Y | 1 |
| Ducray, PS; Endo-Tsukude, C; Gardner, I; Gill, KL; Hatley, OJ; Machavaram, KK; Parrott, N; Terao, K | 1 |
| Chiasson, JL; Grangeon, A; Gravel, S; Michaud, V; Turgeon, J | 1 |
| Aboagye, EO; Clarke, S; Edwards, RJ; Lee, P; Liddle, C; Lozan-Kuehne, JP; Maslen, L; Ramaswami, R; Sharma, R; Trousil, S | 1 |
| Enejosa, JV; Feng, T; Fisniku, O; Mohamed, MF; Othman, AA | 1 |
| Ishida, C; Kotake, Y; Sanoh, S | 1 |
| Eagles, SK; Gross, AS; McLachlan, AJ; Wang, X | 1 |
| Chen, D; Piantone, A; Sharma, A; Shu, C; Xu, Y; Xu, Z; Zhou, H; Zhu, Y; Zhuang, Y | 1 |
| Hakamata, A; Inui, N; Kamiya, C; Katayama, N; Kawakami, J; Miura, M; Namiki, N; Odagiri, K; Tanaka, S; Uchida, S; Watanabe, H | 1 |
| Brantley, SJ; Dai, X; Goulet, MT; Hard, ML; Hitron, M; Karol, MD; McLaughlin, CF | 1 |
| Agarwal, S; Clausen, VA; Harper, P; Najafian, N; Robbie, GJ; Sardh, E; Simon, AR; Vassiliou, D | 1 |
| Ang, DSW; Ang, TL; Benech, H; Koo, SH; Lee, EJD; Pruvost, A; Soon, GH | 1 |
| Bachmann, F; Bouitbir, J; Duthaler, U; Grandinetti, T; Haschke, M; Hruz, P; Krähenbühl, S; Pfefferkorn, F; Suenderhauf, C | 1 |
| Newman, EM; Rowland, A | 1 |
| Chen, SY; Chen, Y; Gong, ZP; Huang, J; Huang, Y; Li, Y; Li, YT; Wang, YL; Yang, HL; Zheng, L | 1 |
| Bansal, S; Paine, MF; Spindle, TR; Thummel, KE; Unadkat, JD; Vandrey, R; Weerts, EM; Zamarripa, CA | 1 |
| Ah-See, ML; Edenfield, WJ; Lewis, LD; Li, Y; Mugundu, GM; Nadeau, L; Någård, M; Ottesen, LH; Safran, HP; Strauss, J; Wise-Draper, T | 1 |
| Aarnoutse, RE; Boeree, MJ; Coenen, MJH; Colbers, A; Dawson, R; Diacon, AH; Fuhr, U; Jager, Vd; Narunsky, K; Padayachee, SD; Phillips, PPJ; Stemkens, R; Svensson, EM; Te Brake, LHM; van Beek, SW | 1 |
3 review(s) available for omeprazole and caffeine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
A Physiologically Based Pharmacokinetic Model to Predict the Impact of Metabolic Changes Associated with Metabolic Associated Fatty Liver Disease on Drug Exposure.
Topics: Animals; Caffeine; Clozapine; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Dextromethorphan; Metoprolol; Midazolam; Non-alcoholic Fatty Liver Disease; Omeprazole; Rosiglitazone; Warfarin | 2022 |
46 trial(s) available for omeprazole and caffeine
| Article | Year |
|---|---|
Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Breath Tests; Caffeine; Carbon Dioxide; Carbon Isotopes; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Induction; Female; Humans; Male; Mephenytoin; Middle Aged; Mixed Function Oxygenases; Omeprazole; Oxidoreductases; Phenotype | 1992 |
Omeprazole treatment does not affect the metabolism of caffeine.
Topics: Adult; Arylamine N-Acetyltransferase; Caffeine; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Double-Blind Method; Enzyme Induction; Humans; Male; Omeprazole; Oxidoreductases; Xanthine Oxidase | 1991 |
A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Alcohol Drinking; Anti-Ulcer Agents; Caffeine; Double-Blind Method; Drug Evaluation; Esophagitis, Peptic; Female; Gastroscopy; Humans; Lansoprazole; Longitudinal Studies; Male; Omeprazole; Proton Pump Inhibitors; Ranitidine; Smoking | 1995 |
Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Enzyme Induction; Enzyme Inhibitors; Female; Humans; Hydroxylation; Lansoprazole; Male; Methylation; Middle Aged; Omeprazole; Oxidoreductases; Proton Pump Inhibitors | 1996 |
Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Area Under Curve; Benzimidazoles; Breath Tests; Caffeine; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 1998 |
Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole.
Topics: Adult; Anti-Ulcer Agents; Antihypertensive Agents; Benzhydryl Compounds; Caffeine; Central Nervous System Stimulants; Cresols; Cross-Over Studies; Cytochromes; Debrisoquin; Drug Interactions; Humans; Male; Muscarinic Antagonists; Omeprazole; Phenylpropanolamine; Polymorphism, Genetic; Tolterodine Tartrate; Urinary Bladder Diseases | 1999 |
Pantoprazole lacks induction of CYP1A2 activity in man.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Area Under Curve; Benzimidazoles; Caffeine; Central Nervous System Stimulants; Cross-Over Studies; Cytochrome P-450 CYP1A2; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Humans; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; Xanthine Oxidase | 1999 |
Omeprazole weakly inhibits CYP1A2 activity in man.
Topics: Adult; Binding, Competitive; Biomarkers; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Humans; In Vitro Techniques; Male; Microsomes, Liver; Omeprazole; Single-Blind Method; Theophylline | 1999 |
Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
Topics: Adrenergic Agents; Adult; Area Under Curve; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2 Inhibitors; Debrisoquin; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Fluvoxamine; Humans; Male; Middle Aged; Omeprazole; Selective Serotonin Reuptake Inhibitors | 2002 |
Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2.
Topics: Adult; Caffeine; Cytochrome P-450 CYP1A2; Enzyme Inhibitors; Gene Frequency; Genotype; Humans; Male; Omeprazole; Phosphodiesterase Inhibitors; Polymorphism, Genetic | 2002 |
Influence of the urine flow rate on some caffeine metabolite ratios used to assess CYP1A2 activity.
Topics: Adolescent; Adult; Biotransformation; Caffeine; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2; Enzyme Induction; Female; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Urodynamics | 2002 |
Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
Topics: Acetyltransferases; Adult; Aryl Hydrocarbon Hydroxylases; Biomarkers; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Genotype; Humans; Midazolam; Middle Aged; Mixed Function Oxygenases; Omeprazole; Oxidoreductases, N-Demethylating; Phenotype; Phosphodiesterase Inhibitors; Reproducibility of Results; Vitamins; Warfarin; Xanthine Oxidase | 2003 |
Omeprazole treatment: genotoxicity biomarkers, and potential to induce CYP1A2 activity in humans.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Caffeine; Cell Division; Chromosome Aberrations; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Enzyme Induction; Female; Genotype; Humans; Male; Micronuclei, Chromosome-Defective; Middle Aged; Mitotic Index; Mixed Function Oxygenases; Mutagens; Omeprazole; Sister Chromatid Exchange | 2004 |
Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction.
Topics: Adult; Caffeine; Cytochrome P-450 Enzyme System; Debrisoquin; Female; Gene Expression Regulation, Enzymologic; Humans; Leukocytes, Mononuclear; Male; Midazolam; Omeprazole; Rifampin; RNA, Messenger | 2005 |
Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail.
Topics: Adult; Arylamine N-Acetyltransferase; Caffeine; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Drug Interactions; Ethinyl Estradiol; Female; Genotype; Humans; Midazolam; Norgestrel; Omeprazole; Therapeutic Equivalency; Vitamin K; Warfarin; Xanthine Oxidase | 2005 |
Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail.
Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoates; Caffeine; CCR5 Receptor Antagonists; Dextromethorphan; Diketopiperazines; Drug Interactions; Female; Humans; Male; Midazolam; Middle Aged; Omeprazole; Piperazines; Spiro Compounds; Warfarin | 2006 |
Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo.
Topics: Administration, Oral; Adult; Aryl Hydrocarbon Hydroxylases; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Genotype; Humans; Isoenzymes; Linear Models; Losartan; Male; Midazolam; Mixed Function Oxygenases; Omeprazole; Phenotype; Polymerase Chain Reaction; Reference Values; Time Factors | 2007 |
Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol.
Topics: Adult; Anti-Ulcer Agents; Antibiotics, Antitubercular; Antihypertensive Agents; Antimalarials; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 Enzyme System; Drug Combinations; Enzyme Induction; Female; Humans; Hydroxycholesterols; Losartan; Male; Middle Aged; Omeprazole; Quinine; Rifampin | 2008 |
Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
Topics: Administration, Oral; Adult; Anti-Anxiety Agents; Anti-Ulcer Agents; Anticoagulants; Area Under Curve; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Humans; Male; Metabolic Clearance Rate; Midazolam; Omeprazole; Warfarin; Young Adult | 2009 |
Repeated administration of berberine inhibits cytochromes P450 in humans.
Topics: Adult; Berberine; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme Inhibitors; Dextromethorphan; Drug Interactions; Drugs, Chinese Herbal; Enzyme Inhibitors; Humans; Losartan; Male; Midazolam; Omeprazole; Young Adult | 2012 |
Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Biotransformation; Caffeine; Case-Control Studies; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Dextromethorphan; Diuretics; Excitatory Amino Acid Antagonists; Female; Furosemide; GABA Modulators; Gastric Bypass; Humans; Hypoglycemic Agents; Male; Midazolam; Middle Aged; Omeprazole; Pharmacokinetics; Tandem Mass Spectrometry; Tolbutamide; Young Adult | 2013 |
A cytochrome P450 phenotyping cocktail causing unexpected adverse reactions in female volunteers.
Topics: Adult; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Drug Combinations; Female; Genotype; Healthy Volunteers; Humans; Losartan; Male; Middle Aged; Omeprazole; Phenotype; Tramadol; Young Adult | 2013 |
The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.
Topics: Adolescent; Adult; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Female; Healthy Volunteers; Humans; Male; Midazolam; Middle Aged; Nitriles; Omeprazole; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Theophylline; Warfarin; Young Adult | 2014 |
Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions.
Topics: Adult; Antihypertensive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Calcium Channel Blockers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Felodipine; Female; Genotype; Humans; Losartan; Male; Midazolam; Omeprazole; Young Adult | 2014 |
Short-term fasting alters cytochrome P450-mediated drug metabolism in humans.
Topics: Adult; Animals; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Fasting; Gene Expression Regulation, Enzymologic; Humans; Liver; Male; Metabolic Clearance Rate; Metoprolol; Midazolam; Omeprazole; Rats, Wistar; Warfarin; Young Adult | 2015 |
Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study.
Topics: Adult; Area Under Curve; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Female; Humans; Lisdexamfetamine Dimesylate; Male; Midazolam; Omeprazole | 2015 |
Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Caffeine; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Interleukin-6; Male; Midazolam; Middle Aged; Omeprazole; Warfarin; Young Adult | 2015 |
Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study.
Topics: Adult; Alkynes; Benzoxazines; Caffeine; Cross-Over Studies; Cyclopropanes; Cytochrome P-450 Enzyme Inhibitors; Genotype; Humans; Losartan; Male; Metoprolol; Midazolam; Omeprazole; Phenotype; Young Adult | 2016 |
A limited sampling strategy based on maximum a posteriori Bayesian estimation for a five-probe phenotyping cocktail.
Topics: Bayes Theorem; Caffeine; Computer Simulation; Dextromethorphan; Drug Interactions; Humans; Midazolam; Models, Biological; Omeprazole; Phenotype; Pilot Projects; Tolbutamide | 2016 |
Effect of commercial Rhodiola rosea on CYP enzyme activity in humans.
Topics: Adult; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Humans; Losartan; Male; Midazolam; Omeprazole; Plant Extracts; Rhodiola; Young Adult | 2016 |
Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
Topics: Adolescent; Adult; Bupropion; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Dose-Response Relationship, Drug; Dried Blood Spot Testing; Drug Interactions; Female; Flurbiprofen; Genotyping Techniques; Humans; Male; Midazolam; Omeprazole; Phenotype; Terfenadine; Young Adult | 2016 |
Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.
Topics: Adult; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Female; Humans; Imidazoles; Male; Midazolam; Middle Aged; Omeprazole; Pituitary ACTH Hypersecretion; Pyridines | 2017 |
Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach.
Topics: Administration, Intravenous; Administration, Oral; Adult; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Drug Combinations; Fasting; Healthy Volunteers; Humans; Male; Metoprolol; Midazolam; Omeprazole; Pharmaceutical Preparations; Time Factors; Warfarin; Young Adult | 2017 |
Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Caffeine; Chromatography, High Pressure Liquid; Cross-Over Studies; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Midazolam; Middle Aged; Neoplasms; Omeprazole; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Tandem Mass Spectrometry; Warfarin | 2018 |
Short-Term Fasting Alters Pharmacokinetics of Cytochrome P450 Probe Drugs: Does Protein Binding Play a Role?
Topics: Administration, Intravenous; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Fasting; Humans; Male; Metoprolol; Midazolam; Omeprazole; Pharmaceutical Preparations; Protein Binding; Warfarin | 2018 |
Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol.
Topics: Adult; Area Under Curve; Caffeine; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Female; Humans; Losartan; Male; Midazolam; Modafinil; Omeprazole; Phenotype; Time Factors; Young Adult | 2018 |
Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.
Topics: Administration, Oral; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Female; Humans; Injections, Subcutaneous; Interleukin-23 Subunit p19; Male; Midazolam; Middle Aged; Omeprazole; Psoriasis; Severity of Illness Index; Treatment Outcome; Warfarin; Young Adult | 2018 |
Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.
Topics: Antibodies, Monoclonal; Area Under Curve; Caffeine; Chronic Disease; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Injections, Subcutaneous; Male; Midazolam; Omeprazole; Psoriasis; Severity of Illness Index; Substrate Specificity; Warfarin | 2019 |
Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation.
Topics: Adult; Aged; Aged, 80 and over; C-Reactive Protein; Caffeine; Chlorzoxazone; Cytochrome P-450 Enzyme System; Cytokines; Dextromethorphan; Female; Humans; Inflammation; Middle Aged; Omeprazole; Ovarian Neoplasms | 2019 |
Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail.
Topics: Adult; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Drug Interactions; Female; Genotype; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Male; Midazolam; Middle Aged; Omeprazole; Phenotype; Vitamin K; Warfarin | 2020 |
Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Area Under Curve; Caffeine; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Omeprazole; Psoriasis; Severity of Illness Index; Warfarin; Young Adult | 2020 |
Prediction of the Area under the Curve Using Limited-Point Blood Sampling in a Cocktail Study to Assess Multiple CYP Activities.
Topics: Administration, Oral; Adult; Area Under Curve; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Humans; Losartan; Male; Midazolam; Models, Biological; Omeprazole; Young Adult | 2021 |
Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers.
Topics: Administration, Oral; Adult; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzofurans; Bupropion; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Female; Flurbiprofen; Gene Expression Regulation; Half-Life; Healthy Volunteers; Humans; Male; Midazolam; Naphthoquinones; Neoplasm Proteins; Omeprazole; Rosuvastatin Calcium; Young Adult | 2021 |
A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver.
Topics: 5-Aminolevulinate Synthetase; Acetylgalactosamine; Adult; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Activation; Female; Humans; Liver; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Omeprazole; Porphyrias, Hepatic; Pyrrolidines; RNA, Small Interfering | 2021 |
Evaluation of a six-probe cocktail (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam, and digoxin) approach to estimate hepatic drug detoxification capability and dosage requirements after a single oral dosing in healthy Chinese volunteers.
Topics: Caffeine; China; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Healthy Volunteers; Humans; Midazolam; Omeprazole; Tolbutamide | 2022 |
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Midazolam; Middle Aged; Neoplasms; Omeprazole | 2023 |
60 other study(ies) available for omeprazole and caffeine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
Topics: 1-Methyl-3-isobutylxanthine; Cell Line; Cell Membrane Permeability; Humans; Models, Biological; Quantitative Structure-Activity Relationship; Skin Absorption | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Omeprazole and hepatic monooxygenase.
Topics: Animals; Caffeine; Callithrix; Dealkylation; Enzyme Induction; Female; Liver; Omeprazole | 1992 |
Lack of pharmacokinetic interaction as an equivalence problem.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absorption; Adenosine Triphosphatases; Administration, Oral; Adult; Benzimidazoles; Caffeine; Drug Interactions; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Models, Biological; Omeprazole; Pantoprazole; Pharmacokinetics; Sulfoxides; Theophylline; Therapeutic Equivalency | 1991 |
Omeprazole and the metabolism of caffeine.
Topics: Caffeine; Duodenal Ulcer; Humans; Omeprazole; Research Design; Statistics as Topic; Stomach Ulcer | 1995 |
Specific and dose-dependent enzyme induction by omeprazole in human beings.
Topics: Absorption; Adolescent; Adult; Aged; Aged, 80 and over; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Induction; Female; gamma-Glutamyltransferase; Glutarates; Half-Life; Humans; Hydrocortisone; Male; Mephenytoin; Methylation; Middle Aged; Omeprazole; Oxidoreductases | 1994 |
Four-week treatment with omeprazole increases the metabolism of caffeine.
Topics: Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Enzyme Induction; Esophagitis; Female; Humans; Liver; Male; Middle Aged; Omeprazole; Oxidoreductases; Peptic Ulcer; Time Factors | 1994 |
Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breath Tests; Caffeine; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Enzyme Induction; Female; Humans; Male; Mephenytoin; Middle Aged; Omeprazole; Oxidoreductases, N-Demethylating; Phenotype; Theophylline; Uric Acid | 1994 |
Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Topics: Administration, Oral; Adult; Anti-Anxiety Agents; Anti-Ulcer Agents; Antitussive Agents; Aryl Hydrocarbon Hydroxylases; Arylamine N-Acetyltransferase; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Drug Interactions; Female; Genotype; Humans; Hypnotics and Sedatives; Male; Midazolam; Middle Aged; Mixed Function Oxygenases; Omeprazole; Oxidoreductases, N-Demethylating; Phenotype; Polymerase Chain Reaction; Xanthine Oxidase | 2000 |
A simplified analytical method for a phenotyping cocktail of major CYP450 biotransformation routes.
Topics: Biotransformation; Caffeine; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Dextromethorphan; Flurbiprofen; Humans; Isoenzymes; Midazolam; Omeprazole; Phenotype; Reproducibility of Results; Sensitivity and Specificity | 2004 |
Rate-limiting biotransformation of triamterene is mediated by CYP1A2.
Topics: Caffeine; Chromatography, High Pressure Liquid; Coumarins; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erythromycin; Humans; Hydroxylation; Ketoconazole; Kinetics; Microsomes, Liver; Omeprazole; Quinidine; Substrate Specificity; Sulfuric Acid Esters; Theophylline; Triamterene | 2005 |
Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Aryl Hydrocarbon Hydroxylases; Biomarkers; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Enzyme Induction; Female; HIV Protease Inhibitors; HIV Seronegativity; Humans; Injections, Intravenous; Intestinal Mucosa; Intestines; Liver; Lopinavir; Male; Midazolam; Middle Aged; Mixed Function Oxygenases; Omeprazole; Pyrimidinones; Ritonavir; Substrate Specificity; Warfarin | 2006 |
A high-throughput assay using liquid chromatography-tandem mass spectrometry for simultaneous in vivo phenotyping of 5 major cytochrome p450 enzymes in patients.
Topics: Biotransformation; Caffeine; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Dextromethorphan; Humans; Losartan; Midazolam; Omeprazole; Phenotype; Tandem Mass Spectrometry | 2009 |
Effects of Angelicae tenuissima radix, Angelicae dahuricae radix and Scutellariae radix extracts on cytochrome P450 activities in healthy volunteers.
Topics: Adult; Angelica; Aryl Hydrocarbon Hydroxylases; Caffeine; Chlorzoxazone; Chromatography, High Pressure Liquid; Chromatography, Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2E1; Dextromethorphan; Drugs, Chinese Herbal; Herb-Drug Interactions; Humans; Losartan; Male; Midazolam; Omeprazole; Phytotherapy; Republic of Korea; Scutellaria baicalensis; Tandem Mass Spectrometry; Young Adult | 2009 |
Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis.
Topics: Administration, Oral; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzoates; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Flurbiprofen; Humans; Hydrazines; Isoenzymes; Male; Midazolam; Omeprazole; Pharmaceutical Preparations; Pyrazoles; Receptors, Thrombopoietin | 2010 |
Cocktail approach for in vivo phenotyping of 5 major CYP450 isoenzymes: development of an effective sampling, extraction, and analytical procedure and pilot study with comparative genotyping.
Topics: Adult; Caffeine; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Dextromethorphan; Female; Genotype; Humans; Isoenzymes; Male; Midazolam; Omeprazole; Phenotype; Pilot Projects; Tandem Mass Spectrometry; Tolbutamide; Young Adult | 2012 |
High-sensitivity liquid chromatography-tandem mass spectrometry for the simultaneous determination of five drugs and their cytochrome P450-specific probe metabolites in human plasma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Caffeine; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Drug Stability; Humans; Imidazoles; Linear Models; Liquid-Liquid Extraction; Losartan; Omeprazole; Pharmaceutical Preparations; Reproducibility of Results; Tandem Mass Spectrometry; Tetrazoles; Theophylline | 2012 |
Inhibitory effects of kale ingestion on metabolism by cytochrome P450 enzymes in rats.
Topics: Administration, Oral; Animals; Area Under Curve; Brassica; Caffeine; Chlorzoxazone; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Cytochromes; Dextromethorphan; Enzyme Inhibitors; Herb-Drug Interactions; Liver; Metabolic Clearance Rate; Midazolam; Omeprazole; Rats; RNA, Messenger; Tolbutamide | 2012 |
Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs.
Topics: Administration, Oral; Animals; Biological Availability; Caffeine; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Drug Combinations; Female; Humans; Injections, Intravenous; Male; Metoprolol; Midazolam; Models, Animal; Omeprazole; Substrate Specificity; Swine; Swine, Miniature; Tandem Mass Spectrometry; Warfarin | 2012 |
Evaluation of the effect of TM208 on the activity of five cytochrome P450 enzymes using on-line solid-phase extraction HPLC-DAD: a cocktail approach.
Topics: Administration, Oral; Animals; Antipyrine; Caffeine; Chlorzoxazone; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Dapsone; Limit of Detection; Linear Models; Male; Metoprolol; Omeprazole; Piperazines; Random Allocation; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Solid Phase Extraction | 2013 |
Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method.
Topics: Adult; Antibiotics, Antitubercular; Asian People; Caffeine; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Imidazoles; Losartan; Male; Midazolam; Omeprazole; Rifampin; Tetrazoles; Theophylline; Time Factors; Withholding Treatment | 2013 |
Simultaneous and comprehensive in vivo analysis of cytochrome P450 activity by using a cocktail approach in rats.
Topics: Animals; Caffeine; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dexamethasone; Dextromethorphan; Drug Interactions; Fluconazole; Fluvoxamine; Ketoconazole; Losartan; Male; Midazolam; Omeprazole; Rats, Sprague-Dawley | 2014 |
Simultaneous LC-MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bupropion; Caffeine; Calibration; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Dextromethorphan; Dried Blood Spot Testing; Flurbiprofen; Half-Life; Male; Midazolam; Omeprazole; Pharmaceutical Preparations; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine | 2014 |
A rapid and simple LC-MS/MS method for the simultaneous evaluation of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 hydroxylation capacity.
Topics: Caffeine; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Humans; Hydroxylation; Losartan; Omeprazole; Tandem Mass Spectrometry | 2014 |
Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.
Topics: Administration, Oral; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bupropion; Caffeine; Capsules; Carbonated Beverages; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Coffee; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Dried Blood Spot Testing; Enzyme Inhibitors; Feasibility Studies; Flurbiprofen; Humans; Isoenzymes; Male; Midazolam; Omeprazole; Pharmaceutical Preparations; Phenotype; Pilot Projects; Predictive Value of Tests; Spectrometry, Mass, Electrospray Ionization; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine; Young Adult | 2014 |
Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation.
Topics: Administration, Oral; Age Factors; Animals; Caffeine; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Female; Macaca fascicularis; Male; Metoprolol; Microsomes, Liver; Midazolam; Models, Animal; Models, Biological; Omeprazole; Warfarin | 2015 |
Evaluation of the impact of Polygonum capitatum, a traditional Chinese herbal medicine, on rat hepatic cytochrome P450 enzymes by using a cocktail of probe drugs.
Topics: Animals; Area Under Curve; Caffeine; Chlorzoxazone; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Liver; Male; Midazolam; Omeprazole; Plant Extracts; Polygonum; Rats; Rats, Sprague-Dawley; Tolbutamide | 2014 |
Sex differences in liver toxicity-do female and male human primary hepatocytes react differently to toxicants in vitro?
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Caffeine; Calcium; Cell Membrane Permeability; Cell Survival; Cells, Cultured; Chlorpromazine; Diclofenac; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Female; Hepatocytes; Humans; Male; Membrane Potential, Mitochondrial; Omeprazole; Primary Cell Culture; Sex Characteristics; Verapamil | 2015 |
Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling.
Topics: Administration, Intravenous; Administration, Oral; Animals; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Humans; Macaca fascicularis; Microsomes, Liver; Midazolam; Models, Biological; Omeprazole; Pharmacokinetics; Warfarin | 2015 |
Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus).
Topics: Administration, Intravenous; Administration, Oral; Animals; Biological Availability; Caffeine; Callithrix; Chromatography, Liquid; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Humans; Intestine, Small; Liver; Metoprolol; Midazolam; Models, Animal; Omeprazole; Tandem Mass Spectrometry; Warfarin | 2016 |
Multiplex Phenotyping for Systems Medicine: A One-Point Optimized Practical Sampling Strategy for Simultaneous Estimation of CYP1A2, CYP2C9, CYP2C19, and CYP2D6 Activities Using a Cocktail Approach.
Topics: Area Under Curve; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Humans; Inactivation, Metabolic; Losartan; Omeprazole; Phenotype; Young Adult | 2016 |
Human plasma concentrations of cytochrome P450 probe cocktails extrapolated from pharmacokinetics in mice transplanted with human hepatocytes and from pharmacokinetics in common marmosets using physiologically based pharmacokinetic modeling.
Topics: Animals; Caffeine; Chimera; Cytochrome P-450 Enzyme System; Dogs; Humans; Macaca fascicularis; Mice; Midazolam; Models, Biological; Omeprazole; Pharmaceutical Preparations; Pharmacokinetics; Swine; Swine, Miniature; Warfarin | 2016 |
Fasting-Induced Changes in Hepatic P450 Mediated Drug Metabolism Are Largely Independent of the Constitutive Androstane Receptor CAR.
Topics: Animals; Caffeine; Constitutive Androstane Receptor; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 2; Fasting; Female; Gene Expression Regulation; Inactivation, Metabolic; Liver; Membrane Proteins; Metoprolol; Mice; Mice, Inbred C57BL; Mice, Knockout; Midazolam; Omeprazole; Receptors, Cytoplasmic and Nuclear; Warfarin | 2016 |
Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Drug Interactions; Fermented Foods; Healthy Volunteers; Humans; Losartan; Male; Midazolam; Middle Aged; Omeprazole; Panax; Pharmaceutical Preparations; Terfenadine; Young Adult | 2016 |
Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19.
Topics: Administration, Intravenous; Aging; Animals; Caffeine; Callithrix; Cytochrome P-450 CYP2C19; Genotype; Humans; Male; Metoprolol; Midazolam; Omeprazole; Rifampin; Substrate Specificity; Warfarin | 2018 |
Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects.
Topics: Adult; Aged; Aged, 80 and over; Caffeine; Chenodeoxycholic Acid; Cholangitis; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Midazolam; Middle Aged; Omeprazole; Rosuvastatin Calcium; Warfarin | 2017 |
Influence of Shenxiong Glucose Injection on the Activities of Six CYP Isozymes and Metabolism of Warfarin in Rats Assessed Using Probe Cocktail and Pharmacokinetic Approaches.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Caffeine; Chlorzoxazone; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P450 Family 2; Drugs, Chinese Herbal; Enzyme Activation; Herb-Drug Interactions; Isoenzymes; Midazolam; Omeprazole; Rats; Steroid 16-alpha-Hydroxylase; Tolbutamide; Warfarin | 2017 |
A Comprehensive In Vivo and In Vitro Assessment of the Drug Interaction Potential of Red Ginseng.
Topics: Adult; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Humans; Liver-Specific Organic Anion Transporter 1; Losartan; Male; Midazolam; Omeprazole; Panax; Plant Preparations; Random Allocation; Young Adult | 2018 |
LC-MS/MS analysis of the plasma concentrations of a cocktail of 5 cytochrome P450 and P-glycoprotein probe substrates and their metabolites using subtherapeutic doses.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; Biological Variation, Population; Caffeine; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Healthy Volunteers; Humans; Isoenzymes; Losartan; Male; Metoprolol; Midazolam; Omeprazole; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Terfenadine | 2019 |
Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations.
Topics: Administration, Oral; Adult; Caffeine; Clinical Trials as Topic; Computer Simulation; Cytochrome P-450 Enzyme System; Dextromethorphan; Down-Regulation; Drug Development; Drug Interactions; Female; Humans; Interleukin-6; Male; Midazolam; Middle Aged; Models, Biological; Neuromyelitis Optica; Omeprazole; Rare Diseases; Serum Albumin, Human; Simvastatin; Warfarin | 2019 |
Modulation of CYP450 Activities in Patients With Type 2 Diabetes.
Topics: Adult; Aged; Bupropion; Caffeine; Case-Control Studies; Chlorzoxazone; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Diabetes Mellitus, Type 2; Female; Humans; Interferon-gamma; Interleukin-1beta; Interleukin-6; Male; Midazolam; Middle Aged; Omeprazole; Tolbutamide; Tumor Necrosis Factor-alpha | 2019 |
CYP1A2 Downregulation by Obeticholic Acid: Usefulness as a Positive Control for the In Vitro Evaluation of Drug-Drug Interactions.
Topics: Caffeine; Cells, Cultured; Chenodeoxycholic Acid; Cytochrome P-450 CYP1A2; Down-Regulation; Drug Interactions; Hepatocytes; Humans; Omeprazole; Receptors, Aryl Hydrocarbon; RNA, Messenger; Transcription, Genetic | 2019 |
An improved cytochrome P450 phenotyping cocktail with a simplified and highly sensitive UHPLC-MS/MS assay in human plasma.
Topics: Biosensing Techniques; Caffeine; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Humans; Limit of Detection; Losartan; Midazolam; Omeprazole; Phenotype; Sensitivity and Specificity; Tandem Mass Spectrometry | 2020 |
Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently.
Topics: Caffeine; Child; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Flurbiprofen; Humans; Liver Cirrhosis; Metoprolol; Midazolam; Omeprazole | 2022 |
[Effect of Laportea bulbifera extract on CYP450 enzyme activities in rats by Cocktail probe drug method].
Topics: Animals; Caffeine; Chlorzoxazone; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Metoprolol; Midazolam; Omeprazole; Plant Extracts; Rats; Tandem Mass Spectrometry; Tolbutamide | 2022 |
Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.
Topics: Adult; Caffeine; Cannabidiol; Cannabinoids; Cannabis; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dronabinol; Drug Interactions; Hallucinogens; Humans; Losartan; Midazolam; Omeprazole; Plant Extracts | 2023 |
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
Topics: Adult; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Humans; Midazolam; Omeprazole; Rifampin; Tolbutamide; Tuberculosis, Pulmonary | 2023 |